Advertisement

Dipyridamole Injection

[09 March 2015]

Products Affected - Description

Dipyridamole 5 mg/mL injection, Teva
2 mL vial, 25 count (NDC 00703-1652-04)
10 mL vial, 10 count (NDC 00703-1654-03)
 
Dipyridamole 5 mg/mL injection, West-Ward
10 mL vial (NDC 00641-2569-44)

Reason for the Shortage

Teva has temporarily discontinued their 2 mL and 10 mL products in order to increase the package sizes.

Available Products

There is insufficient supply for usual ordering.

Estimated Resupply Dates

  • Teva has temporarily discontinued dipyridamole 5 mg/mL 2 mL and 10 mL vials. The company cannot estimate a release date for the new presentations.
  • West-Ward has dipyridamole 5 mg/mL 10 mL vials on allocation.

Related Shortages

Updated

March 9, February 4, January 14, 2015; October 20, August 6, April 14, January 8, 2014; October 4, August 1, June 4, March 14, January 14, 2013; December 5, 10, and 21, November 5 and 16, October 4 and 12, August 22, July 25, May 18, March 6, January 18, 2012; December 6, October 5, August 3, June 9, May 4, March 29, February 16, 2011; December 17, November 12, October 11, September 1, August 2, June 9 and 30, April 20, March 9, January 27, 2009; November 25, October 20, September 3, 2008, Drug Information Service, University of Utah, Salt Lake City, UT. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement